Close

News

GSK wins FDA priority review for Promacta supplemental new drug application

GlaxoSmithKline, Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. Eltrombopag, known by the...

Catalent begins supply of Abilify antipsychotic drug to Otsuka Pharma

Catalent has started supplying its antipsychotic drug, Abilify, an orally disintegrating tablet (ODT) to Otsuka Pharmaceutical. Abilify ODT, which utilizes Catalent's Zydis fast dissolve drug delivery technology, is designed to improve manic symptoms associated...

Bloodstream scavenger inhibits clotting without increased bleeding

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges - stopping the formation of blood clots...

Novartis gains FDA approval for Afinitor® in advanced breast cancerNovartis gains FDA approval for Afinitor® in advanced breast cancer

  The US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets* (approval represents the first major advance for US patients with advanced HR+ breast cancer since aromatase inhibitors were introduced more than 15 years ago) for the...

AstraZeneca to initiate a new study of BRILINTA in patients with PAD

AstraZeneca announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America. PAD patients are...

GSK to acquire Human Genome Sciences for US$14.25 per share in cash

GlaxoSmithKline plc and Human Genome Sciences have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The transaction values HGS at approximately US$3.6 billion on an equity...

GSK and Theravance announce regulatory submissions for FF/VI

GlaxoSmithKline plc (GSK) and Theravance, Inc. announced the submission of regulatory applications in the US and European Union for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" (FF/VI) for patients with chronic obstructive pulmonary disease (COPD) and a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »